Right ventricular failure in congenital heart disease

Young Kuk Cho, MD, Jae Sook Ma, MD
Department of Pediatrics, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea

Despite developments in surgical techniques and other interventions, right ventricular (RV) failure remains an important clinical problem in several congenital heart diseases (CHD). RV function is one of the most important predictors of mortality and morbidity in patients with CHD. RV failure is a progressive disorder that begins with myocardial injury or stress, neurohormonal activation, cytokine activation, altered gene expression, and ventricular remodeling. Pressure-overload RV failure caused by RV outflow tract obstruction after total correction of tetralogy of Fallot, pulmonary stenosis, atrial switch operation for transposition of the great arteries, congenitally corrected transposition of the great arteries, and systemic RV failure after the Fontan operation. Volume-overload RV failure may be caused by atrial septal defect, pulmonary regurgitation, or tricuspid regurgitation. Although the measurement of RV function is difficult because of many reasons, the right ventricle can be evaluated using both imaging and functional modalities. In clinical practice, echocardiography is the primary mode for the evaluation of RV structure and function. Cardiac magnetic resonance imaging is increasingly used for evaluating RV structure and function. A comprehensive evaluation of RV function may lead to early and optimal management of RV failure in patients with CHD.

Key words: Right-side heart failure, Right ventricle, Congenital heart disease

Introduction

Progress in new surgical techniques and medical management for congenital heart diseases (CHD) has dramatically improved patient survival over the past decades. However, with many patients with CHD surviving until adulthood, right ventricular (RV) failure has become a concern1. Several types of CHD are associated with RV failure, although surgical or interventional adjustments have been developed for CHD1. RV outflow tract (RVOT) obstruction after total correction of the tetralogy of Fallot (TOF), pulmonary stenosis, atrial switch operation for transposition of the great arteries (TGA), congenitally corrected TGA (ccTGA), and systemic RV failure after the Fontan operation are the causes of pressure-overload RV failure1,2. Another problem is the volume-overload RV failure that may be caused by atrial septal defect (ASD), pulmonary regurgitation, and tricuspid regurgitation1,2. The development of RV failure associated with CHD should be carefully monitored, and both optimal medical and surgical treatments should be considered. The aim of this review is to provide an update on the current understanding of RV failure in patients with CHD.

RV anatomy

In contrast to the ellipsoidal shape of the left ventricle (LV), in the sideward view, the right ventricle appears triangular, and in the cross-sectional view, it appears crescent shaped14. The
right ventricle can be divided into 3 components: 1) the inlet, 2) the trabeculated apical myocardium, and 3) the infundibulum or conus (Fig. 1). The specific morphological features of the anatomy of the right ventricle include the following: 1) the more apical attachment of the septal leaflet of the tricuspid valve relative to the anterior leaflet of the mitral valve, 2) the presence of a moderator band, 3) the presence of >3 papillary muscles, 4) the trileaflet of the tricuspid valve with septal papillary attachments, and 5) the presence of prominent and coarse trabeculations.

Although the right ventricle appears smaller than the LV in the 4-chamber view, the volume of the right ventricle is more than that of the LV. In normal adults, RV mass is only approximately one-sixth that of the LV, and the right ventricle has a wall thickness 3 to 4 times less than that of the LV. Progressive regression of RV hypertrophy is observed as pulmonary vascular resistance (PVR) decreases during childhood.

The right ventricle is linked to the LV at several points such as a shared ventricular septal wall, mutually encircling epicardial fibers, attachment of the RV free wall to the anterior and posterior septum, and sharing the pericardial space.

RV physiology

The essential function of the right ventricle is to receive systemic venous blood and pump it into the pulmonary arteries. In the absence of shunt physiology or significant valvular regurgitation, the right ventricle pumps the same stroke volume as the LV. However, the stroke work of the right ventricle is only approximately 25% of that of the LV because of low vascular resistance and pulmonary artery distensibility. Therefore, the right ventricle is thinner walled and more compliant than the LV. RV contraction starts with the inlet and trabeculated myocardium and ends with the infundibulum. In contrast to the LV, twisting and rotational movements do not significantly contract the right ventricle, and RV shortening is greater longitudinally than radially. RV systolic function is a reflection of contractility, afterload, and preload. RV performance is also influenced by heart rhythm, synchrony of ventricular contraction, RV force-interval relationship, and ventricular interdependence.

Compared with the LV, the right ventricle demonstrates a heightened sensitivity to afterload change. In clinical practice, PVR is the most commonly used index of afterload. The PVR is influenced by hypoxia or hypercarbia, cardiac output, pulmonary volume and pressure, and specific molecular pathways such as the nitric oxide, prostaglandin, and endothelin pathways. Excessive RV volume can compress the LV and impair global LV function through the effects of ventricular interdependence. The main structures for ventricular interdependence include the ventricular septum, pericardium, and continuity between myocardial fibers of the right ventricle and LV. In acute RV pressure- or volume-overload states, dilatation of the right ventricle shifts the interventricular septum toward the left, altering LV geometry. This leads to a decreased LV preload, an increased LV end-diastolic pressure, or low cardiac output.

The pressure-overloaded right ventricle

When the right ventricle is exposed to pressure overload, progressive dilatation follows a primary adaptive response that includes hypertrophy. Although some reports state that hypertrophy itself is beneficial for overcoming the increased backward pressure, it is well accepted that a persistent increase in the pressure of the right ventricle causes a loss of contractile force that is required for pumping out the blood. Moreover, uncorrected RV failure often induces diastolic dysfunction of the LV. Pressure overload of the right ventricle also may lead to RV ischemia, which may further aggravate ventricular dysfunction. Compared with the volume-overload condition, histological changes are more common in the RV pressure-overload condition, in particular, increased myocardial fibrosis, which is seen in both animal and human studies. Two major conditions of pressure loading of the right ventricle are RVOT obstruction and the right ventricle supporting the systemic circulation.

Isolated pulmonary stenosis is the most common RVOT obstructive CHD. Although the obstruction may also occur at the subvalvar or supravalvar levels, 80% to 90% of cases have valve level obstruction. Regardless of the level of obstruction, the right ventricle exerts a hypertrophic response according to the degree of obstruction. The pressure gradient across the RVOT can be

Fig. 1. Three-dimensional computed tomography images of a normal heart showing the inlet, trabeculated apical myocardium, and infundibulum of the right ventricle.
supports the systemic circulation, because the anatomy of the right ventricle with TGA who have undergone an atrial switch surgery and in patients with moderate-to-severe pulmonary valve stenosis, may lead to RV failure and tricuspid regurgitation. Percutaneous valvuloplasty is considered in patients with moderate-to-severe pulmonary valve stenosis.

In terms of physiology and anatomy, the right ventricle has obvious disadvantages involved in supporting the systemic circulation. It is well suited to changes but is poorly tolerant to acute changes in afterload. Late RV failure usually occurs in patients with TGA who have undergone an atrial switch surgery and in patients with ccTGA, because the anatomy of the right ventricle supports the systemic circulation. The cause of RV dysfunction is unclear. However, myocardial perfusion defects, uncoordinated myocardial contraction, and systemic atrioventricular valve (tricuspid valve) regurgitation contribute to the progressive decline in RV function in patients who have undergone an atrial switch operation. RV dilatation and impaired systolic function correlates inversely with RV systolic function.

In patients with ccTGA, long-term outcome is abnormal even in patients without associated lesions. Moderate-to-severe systemic atrioventricular valve (tricuspid valve) regurgitation and RV failure are associated with increased mortality. RV dysfunction usually starts within 5 years from the onset of TR in ccTGA patients without associated lesions. RV failure with ventricular enlargement also results in TR aggravation due to annular dilatation. Tricuspid valve replacement may slow the progression of RV failure. Among the older patients with ccTGA, many may be considered for mechanical support or heart transplantation.

The volume-overloaded right ventricle

The right ventricle adapts better to volume overload than to pressure overload and may tolerate volume overload for a longer time without significant systolic dysfunction. Recent studies, however, have demonstrated that chronic volume overload is associated with increased morbidity and mortality.

A large ASD results in left-to-right shunting and volume overload of the right ventricle. Large ASDs may remain minimally symptomatic during the high-volume phase, until and Eisenmenger’s syndrome and pulmonary vasculopathy develop. In contrast to patients with ventricular septal defects, only a small percentage of patients with ASD develop Eisenmenger’s syndrome in later life. Age older than 40 years at closure is associated with incomplete right ventricle, right atrial reverse remodeling, and increased risk of arrhythmias. Closure of the ASD is contraindicated in patients with Eisenmenger physiology, unless significant regression of pulmonary vascular disease occurs with pharmacological therapy.

Severe pulmonary regurgitation is the most common cause of progressive RV dilatation and dysfunction in patients with repaired TOF. It is associated with decreased exercise tolerance, arrhythmias, and sudden death. Severe and progressive RV dilatation may be a primary sign of a RV dysfunction, an indication for pulmonary valve replacement. Pulmonary valve replacement generally results in ventricular reverse remodeling with a decrease in RV volume. Advanced severe RV dilatation with an end-diastolic volume >170 mL/m² or an end-systolic volume >85 mL/m² before replacement, however, is associated with persistence of RV dilatation after surgery. In TOF, a “restrictive RV physiology” has been associated with worse outcome after repair of TOF. A restrictive RV physiology is characterized by the presence of forward and laminar late diastolic pulmonary flow throughout respiration. Early after TOF repair, restrictive RV physiology is associated with a low cardiac output and longer intensive care unit stay. Late after TOF repair, however, restrictive RV physiology counteracts the effects of chronic pulmonary regurgitation.

Ebstein anomaly is characterized by an apical displacement of the septal and posterior tricuspid leaflets exceeding 8 mm/m², leading to an atrialized RV and moderate-to-severe tricuspid regurgitation. RV failure in Ebstein anomaly results from volume overload of the right ventricle and from a hypoplastic RV chamber unable to manage the systemic venous blood. In symptomatic patients, the size of the functional RV and tricuspid valve morphology determine the best surgical technique.

Assessment of the right ventricle

Although the measurement of RV function is difficult, the right ventricle can be evaluated using several imaging and functional modalities. In clinical practice, echocardiography is the mainstay for evaluating the RV structure and function. Compared with other modalities, it is versatile and available at all institutes. In addition, Doppler-derived indices such as the myocardial performance index (MPI) and tricuspid annular isovolumic acceleration (IVA) are emerging as promising parameters of RV function. Cardiac magnetic resonance imaging (MRI) is the primary technique for evaluating RV structure and function. MRI is considered the most accurate tool for assessing RV volume. MRI may have an extending future role in assessing the physiological characteristics of pulmonary arterial flow. Radionuclide-based techniques provide reliable and geometrically independent assessments of RV ejection fraction (RVEF).
curves are also useful in the quantification of shunts. Cardiac catheterization provides direct hemodynamic data and allows accurate assessment of PVR. Pulmonary angiography and coronary angiography can further delineate important anatomic and functional characteristics. The simplest method for assessing RV volume includes linear dimensions and areas obtained from single tomographic echocardiographic planes. In an effort to be more accurate, different approaches have been sought to measure RV volume. These include the area-length method and the Simpson’s rule method. Three-dimensional echocardiography is a promising technique that could lead to more accurate measurement of RV volume.

The study of RV function comprises indices that reflect RV systolic function, RV diastolic function, and valvular function. The most commonly used echocardiographic indices of RV systolic function are as follows: 1) geometric indices such as RV fractional area change, RVEF, and tricuspid annular plane systolic excursion (Fig. 2), which reflect the extent of contraction; 2) myocardial velocity indices such as the tricuspid annular plane maximal systolic velocity and the IVA (Fig. 3); 3) hemodynamic indices such as the first RV derivative of pressure and time (RV dP/dt); and 4) time interval indices such as the RV MPI (Fig. 4) or Tei index, which reflect both systolic and diastolic parameters. Right atrial pressure (RAP) is a clinically useful diastolic variable of RV diastolic function. In patients who are not being mechanically ventilated, the inferior vena cava size and collapse index correlate well with RAP. Recent studies showed that serum levels of B-type natriuretic peptide may be useful in diagnosing RV failure associated with CHD. Elevated troponin levels have also been associated with worse outcomes in pulmonary embolism and pulmonary hypertension.

**Management of RV failure**

For the management of RV failure, the cause and setting of the failure should be considered. The ultimate treatment goals include optimization of preload, afterload, and contractility. Maintenance of sinus rhythm and atrioventricular synchrony...
is especially important in RV failure because atrial fibrillation and atioventricular block may have profound hemodynamic effects\textsuperscript{18}. In patients with RV dysfunction and valvular heart disease or CHD, corrective surgery or percutaneous intervention should be considered in suitable candidates\textsuperscript{18,20,40}. Clinically, the assessment of optimal preload in RV failure remains challenging\textsuperscript{18}. If no hemodynamic improvement is observed with an initial fluid challenge of normal saline, volume loading should not be continued\textsuperscript{18}. The hemodynamic improvement seen with nitric oxide is most likely secondary to selective pulmonary vasodilatation, resulting in a reduction in RV afterload and subsequent improvement in RV performance\textsuperscript{41}. Acute responsiveness to pulmonary vasodilators is associated with a better prognosis and survival in patients with advanced heart failure\textsuperscript{45,47}. In patients with acute hemodynamically compromising RV failure, inotropic or vasopressor support may be required\textsuperscript{48}. Dobutamine is the most commonly used inotrope in cases of RV failure\textsuperscript{48}. In patients with pulmonary hypertension, dobutamine at doses of 2–5 μg · kg\textsuperscript{-1} · min\textsuperscript{-1} increases cardiac output but decreases PVR\textsuperscript{48}. The combination of dobutamine and nitric oxide in patients with pulmonary hypertension also has been shown to be beneficial\textsuperscript{49}. Dopamine is used in severely hypotensive patients, whereas milrinone is preferred in the presence of tachyarrhythmias induced by dopamine or in patients on β-blockers\textsuperscript{40}. Digoxin therapy for RV failure has been studied in pulmonary hypertension and chronic pulmonary disease\textsuperscript{48}. Maintenance of sinus rhythm and heart rate control are important in RV failure. High-degree AV block or atrial fibrillation may have profound hemodynamic consequences\textsuperscript{18}. The RVEF in patients with either systemic or pulmonic RV was improved by cardiac resynchronization therapy\textsuperscript{40}. The effects of β-blockade and angiotensin-converting enzyme inhibition have been studied mainly in LV heart failure. In patients with biventricular failure, angiotensin-converting enzyme inhibition has been shown to increase RVEF and to reduce RV end-diastolic volume and filling pressures\textsuperscript{48}. Small studies also have demonstrated that β-blockade with carvedilol or bisoprolol improves RV systolic function\textsuperscript{47}. Clinical studies that assessed the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the systemic right ventricle found that they do not improve exercise capacity or hemodynamics, although those studies may have been underpowered\textsuperscript{48}. In patients with acute RV failure that is refractory to medical treatment, mechanical support with an right ventricle assisting device may be used as a bridge to transplantation or recovery\textsuperscript{18}. The development of new therapeutic strategies for RV failure is warranted. These new strategies might include cell-based or gene therapies, new drugs, or new combinations of existing drugs\textsuperscript{0}.

Conclusions

RV failure remains an important cause of morbidity and mortality in patients with CHD both before and after cardiac surgery or intervention. Although recent advances in imaging including cardiac MRI, echocardiography remains pivotal for the noninvasive assessment of the right ventricle. A comprehensive evaluation of RV function may improve risk assessment and lead to early and optimal management of RV failure in patients with CHD.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

References

1. Davlouros PA, Niwa K, Webb G, Gatzoulis MA. The right ventricle in congenital heart disease. Heart 2006;92 Suppl 1:227-38.
2. Voelkel NF, Quaiife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006;114:1883-91.
3. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 2008;117:1436-48.
4. Haddad F, Couture P, Tousignant C, Denault AT. The right ventricle in cardiac surgery, a perioperative perspective: I. Anatomy, physiology, and assessment. Anesth Analg 2009;108:407-21.
5. Ho SY, Nihoyannopoulos P. Anatomy, echocardiography, and normal right ventricular dimensions. Heart 2006;92 Suppl 1:12-13.
6. Lorenz CH, Walker ES, Morgan VL, Klein SS, Graham TP Jr. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson 1999;1:7-21.
7. Kvasnicka J, Vokrouhlický L. Heterogeneity of the myocardium. Function of the left and right ventricle under normal and pathologic conditions. Physiol Res 1991;40:31-7.
8. Petitjean C, Rougon N, Chupel P. Assessment of myocardial function: a review of quantification methods and results using tagged MRI. J Cardiovasc Magn Reson 2005;7:501-16.
9. Dell’Italia LJ. Mechanism of postextrasystolic potentiation in the right ventricle. Am J Cardiol 1990;65:736-41.
10. Goldstein JA, Barzilai B, Rosamond TL, Eisenberg PR, Jaffe AS. Determinants of hemodynamic compromise with severe right ventricular infarction. Circulation 1990;82:359-68.
11. Feneley MP, Gavaghan TP, Baron DW, Branson JA, Roy PR, Morgan JJ. Contribution of left ventricular contraction to the generation of right ventricular systolic pressure in the human heart. Circulation 1985;71:473-80.
12. Santamore WP, Dell’Italia LJ. Ventricular interdependence: significant left ventricular contributions to right ventricular systolic
function. Prog Cardiovasc Dis 1998;40:289-308.
13. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med 1994;150: 833-52.
14. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 2005;16:13-8.
15. Dell'Italia LJ. The right ventricle: anatomy, physiology, and clinical importance. Curr Probl Cardiol 1991;16:653-720.
16. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006;114:1417-31.
17. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation 2004;109:1580-9.
18. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 2008;117:1717-31.
19. Marino TA, Kent RL, Uboh CE, Fernandez E, Thompson EW, Cooper G 4th. Structural analysis of pressure versus volume overload hypertrophy of cat right ventricle. Am J Physiol 1985;249(2 Pt 2): H371-9.
20. Kasimir MT, Seebacher G, Jaksh P, Winkler G, Schmid K, Marta GM, et al. Reverse cardiac remodelling in patients with primary pulmonary hypertension after isolated lung transplantation. Eur J Cardiotherac Surg 2004;26:776-81.
21. Graham TP Jr. Ventricular performance in congenital heart disease. Circulation 1991;84:2259-74.
22. Currie PJ, Hagler DJ, Seward JB, Reeder GS, Fyfe DA, Bove AA, et al. Instantaneous pressure gradient: a simultaneous Doppler and dual catheter correlative study. J Am Coll Cardiol 1986;7:800-6.
23. Warnes CA. Transposition of the great arteries. Circulation 2006;114:2699-709.
24. Millane T, Bernard EJ, Jaeggi E, Howman-Giles RB, Uren RF, Cartmill TB, et al. Role of ischemia and infarction in late right ventricular dysfunction after atrial repair of transposition of the great arteries. J Am Coll Cardiol 2000;35:1661-8.
25. Babu-Narayan SV, Goktekin O, Moon JC, Broberg CS, Pantely GA, Pannell DJ, et al. Late gadolinium enhancement cardiovascular magnetic resonance of the systemic right ventricle in adults with previous atrial redirection surgery for transposition of the great arteries. Circulation 2005;111:2091-8.
26. van Son JA, Danielson GK, Huhta JC, Warnes CA, Edwards WD, Schaff HV, et al. Late results of systemic atroventricular valve replacement in corrected transposition. J Thorac Cardiovasc Surg 1995;109:642-52.
27. Webb G, Gaizoulis MA. Atrial septal defects in the adult: recent progress and overview. Circulation 2006;114:1645-53.
28. Therrien J, Provost Y, Merchant N, Williams W, Colman J, Webb G. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol 2005;95:779-82.
29. Cullen S, Shore D, Redington A. Characterization of right ventricular diastolic performance after complete repair of tetralogy of Fallot. Restrictive physiology predicts slow postoperative recovery. Circulation 1995;91:1782-9.
30. Gatzoulis MA, Clark AL, Cullen S, Newman CG, Redington AN. Right ventricular diastolic function 15 to 35 years after repair of tetralogy of Fallot. Restrictive physiology predicts superior exercise performance. Circulation 1995;91:1775-81.
31. Messika-Zeitoun D, Thomson H, Bellamy M, Scott C, Tribouilloy C, Dearani J, et al. Medical and surgical outcome of tricuspid regurgitation caused by flail leaflets. J Thorac Cardiovasc Surg 2004;128:296-302.
32. Haddad F, Denault AY, Couture P, Cartier R, Pellerin M, Levesque S, et al. Right ventricular myocardial performance index predicts perioperative mortality or circulatory failure in high-risk valvular surgery. J Am Soc Echocardiogr 2007;20:1065-72.
33. Carabello BA. Evolution of the study of left ventricular function: old oil is new again. Circulation 2002;105:2701-3.
34. Yu CM, Sanderson JE, Chan S, Yeung L, Hung YT, Woo KS. Right ventricular diastolic dysfunction in heart failure. Circulation 1996;93:1509-14.
35. Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004;126:1330-6.
36. Oosterhof T, Tulevski II, Vliegen HW, Spijkeroo BM, Mulder BJ. Effects of volume and/or pressure overload secondary to congenital heart disease (tetralogy of fallot or pulmonary stenosis) on right ventricular function using cardiovascular magnetic resonance and B-type natriuretic peptide levels. Am J Cardiol 2006;97:1051-5.
37. Konstantinides S, Geibel A, Olschewski M, Kasper W, Hruska N, Jackle S, et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002;106:1263-8.
38. Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003;108:844-8.
39. Landzberg MJ. Congenital heart disease associated pulmonary arterial hypertension. Clin Chest Med 2007;28:243-53, x.
40. Steele PM, Fuster V, Cohen M, Ritter DG, McCoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease—long-term follow-up and prediction of outcome after surgical correction. Circulation 1987;76:1037-42.
41. Inglessi I, Shin JT, Lepore PJ, Palacios IF, Zapol WM, Bloch KD, et al. Hemodynamic effects of inhaled nitric oxide in right ventricular myocardial infarction and cardiogenic shock. J Am Coll Cardiol 2004;44:793-8.
42. Badescu DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1 Suppl):355-62S.
43. Gavazzi A, Ghio S, Scelsi L, Campagna C, Klersy C, Serio A, et al. Response of the right ventricle to acute pulmonary vasodilatation predicts the outcome in patients with advanced heart failure and pulmonary hypertension. Am Heart J 2003;145:310-6.
44. Vizza CD, Rocca GD, Roma AD, Iacombi C, Pierconti F, Venuta F, et al. Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. Crit Care Med 2001;5:355-61.
45. Dubin AM, Janousek J, Rhee E, Strieper MJ, Cecchin F, Law IH, et al. Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. J Am Coll Cardiol 2003;42:2277-83.
46. Massie B, Kramer BL, Topic N, Henderson SG. Hemodynamic and radionuclide effects of acute captopril therapy for heart failure: changes in left and right ventricular volumes and function at rest and during exercise. Circulation 1982;65:1374-81.
47. Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow MR. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol 1998;81:247-50.
48. Dore A, Houde C, Chan KL, Ducharme A, Khairy P, Juneau M, et al. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation 2005;112:2411-6.